Rivaroxaban
| Evidence Level: L4 | Predicted Indications: 4 |
Table of Contents
Rivaroxaban: From Anticoagulation to Rheumatoid Arthritis
One-Sentence Summary
Rivaroxaban is a direct Factor Xa inhibitor used for venous thromboembolism treatment/prophylaxis and stroke prevention in atrial fibrillation. TxGNN’s top prediction suggests possible efficacy in rheumatoid arthritis (score 99.57%), but on review the supporting literature addresses coagulation biomarkers and VTE risk in autoimmune disease — not rivaroxaban treating RA itself — so the signal appears to be a confounded comorbidity association rather than a genuine repurposing lead.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no India licenses on file; clinically rivaroxaban is a DOAC used for VTE/AF stroke prevention) |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on general pharmacological knowledge, rivaroxaban is a direct Factor Xa inhibitor; its efficacy in VTE treatment/prophylaxis and stroke prevention in atrial fibrillation is well established.
The proposed mechanistic link to rheumatoid arthritis — that Factor Xa/thrombin signaling via PAR-1/PAR-2 receptors may contribute to synovial inflammation — is biologically plausible in theory, but none of the retrieved literature actually tests rivaroxaban as a treatment for RA. The three supporting papers cover (1) a general VTE diagnosis/treatment review, (2) thrombin generation assays as a research tool in autoimmune disease, and (3) rivaroxaban vs. apixaban adherence in atrial fibrillation — none evaluate anti-inflammatory or disease-modifying effects in RA patients.
The most likely explanation is that TxGNN’s high score reflects the well-known epidemiological association between RA and elevated VTE risk (RA patients are frequently co-prescribed anticoagulants for comorbid thrombotic disease), rather than a true drug-repurposing signal. This is explicitly flagged in the evidence pack’s own rationale as a case where TxGNN’s score does not indicate a new therapeutic pathway.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33141212 | 2020 | Review | JAMA | General review of DVT/PE diagnosis and treatment; does not address RA or anti-inflammatory use of rivaroxaban |
| 34175144 | 2021 | Review | La Revue de médecine interne | Discusses thrombin generation assay as a tool to assess hypercoagulability in autoimmune disease (e.g., antiphospholipid syndrome); not RA-specific and not a treatment study |
| 29621248 | 2018 | Cohort | PLoS One | Compares medication adherence between rivaroxaban and apixaban in atrial fibrillation; unrelated to RA |
Note: No literature in this evidence pack directly evaluates rivaroxaban as an RA treatment.
India Market Information
Currently no India registration — rivaroxaban is not marketed in the evaluated jurisdiction per this evidence pack (total_licenses: 0).
Safety Considerations
- Drug Interactions: 313 total interactions identified via DDInter. Notable Major-severity interactions include:
- Acetylsalicylic acid (Major)
- Cobicistat (Major)
- Deferasirox (Major)
- Ibritumomab tiuxetan (Major)
- Tositumomab (I-131) (Major)
Additional Moderate-severity interactions include CYP3A4/P-gp modulators such as clarithromycin, cimetidine, dexamethasone, miconazole, clotrimazole, aprepitant, and rolapitant.
Key warnings and contraindications are not available in this evidence pack — please refer to the official package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Rivaroxaban is not currently marketed in this jurisdiction (0 registrations), and the top-ranked predicted indication (rheumatoid arthritis, L4 evidence) is not supported by any literature actually testing anti-inflammatory or RA-specific efficacy — the retrieved evidence reflects comorbidity/DDI research rather than a therapeutic signal. The remaining three candidates in this evidence pack (gout, HIV infectious disease, brachydactyly-syndactyly syndrome) were independently reviewed and also received Hold with L4–L5 evidence; all were flagged as likely confounded associations (DDI/PK studies or coincidental literature co-occurrence) rather than genuine repurposing leads.
To proceed, the following is needed:
- Confirmed original MOA and approved indication data (currently marked as data gaps)
- India/local regulatory filing status and package insert (key warnings, contraindications)
- A mechanistic or preclinical study specifically linking Factor Xa inhibition to RA disease activity, if this candidate is to be revisited
- Re-screening of TxGNN outputs to filter out comorbidity-driven false positives before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.